PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$108.05
as of October 02, 2026 -
YTD RETURNS--
as of October 02, 2026 -
Total Net Assets$1.03B
as of October 02, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 10/01/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.80 |
214,559,710 |
|
MRK |
Merck & Co Inc |
13.33 |
137,536,001 |
|
NVO |
Novo Nordisk A/S |
5.59 |
57,644,134 |
|
PFE |
Pfizer Inc |
5.15 |
53,085,217 |
|
BMY |
Bristol-Myers Squibb Co |
4.80 |
49,528,455 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.77 |
49,225,948 |
|
MCK |
Mckesson Corp |
4.61 |
47,579,936 |
|
GSK |
Gsk Plc |
4.44 |
45,791,823 |
|
COR |
Cencora Inc |
4.38 |
45,221,994 |
|
ABBV |
Abbvie Inc |
3.64 |
37,594,976 |
|
HLN |
Haleon Plc |
3.62 |
37,310,255 |
|
NVS |
Novartis Ag |
3.61 |
37,232,969 |
|
AZN |
Astrazeneca Plc |
3.54 |
36,466,706 |
|
JNJ |
Johnson & Johnson |
3.41 |
35,146,462 |
|
SNY |
Sanofi Sa/France |
3.34 |
34,444,114 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.69 |
27,776,836 |
|
ZTS |
Zoetis Inc |
2.47 |
25,516,488 |
|
VTRS |
Viatris Inc |
1.50 |
15,425,858 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.34 |
13,859,202 |
|
CORT |
Corcept Therapeutics Inc |
0.77 |
7,947,771 |
|
AXSM |
Axsome Therapeutics Inc |
0.73 |
7,551,171 |
|
ELAN |
Elanco Animal Health Inc |
0.49 |
5,044,392 |
|
DFTX |
Definium Therapeutics Inc |
0.49 |
5,029,226 |
|
OGN |
Organon & Co |
0.29 |
3,013,814 |
|
PRGO |
Perrigo Co Plc |
0.10 |
1,056,323 |
|
-USD CASH- |
-- |
0.09 |
960,888 |
|
-- |
Other/Cash |
-0.00 |
-26,796 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 09/30/2026
-
Sector
% of Net Assets -
Health Care
99.62 -
Other/Cash
0.38
Country Weightings (%) as at 09/30/2026
-
Country
% of Net Assets -
United States
67.84 -
United Kingdom
11.75 -
Denmark
5.60 -
Israel
4.75 -
Switzerland
3.61 -
France
3.35 -
Japan
2.71 -
Other/Cash
0.38
Fees
Distributions
as of 10/02/2026
Quarterly
1.89%
1.33%
1.98%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency